Excess body weight—including overweight and obesity—is a significant risk factor for cancer. Research from the American Cancer Society estimates that it contributes to approximately 5 percent of ...

Breast cancer remains a major global health challenge, with treatment strategies varying widely across regions.

Aditya Bardia, MD, MPH, FASCO, medical oncologist, UCLA Health, discusses findings from the TROPION-Breast01 study on ...

Cancer breakthrough as scientists find way to spot aggressive tumours before they spread - The discovery could pave the way ...

Relay Therapeutics' financial stability is strong, but zero Q3 2024 revenue and rising net losses raise concerns. Find out ...

Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines mark a significant milestone in breast cancer treatment, seamlessly integrating cutting-edge international research with Chinese ...

Dr. Debu Tripathy discusses the FDA approval of Enhertu in unresectable or metastatic hormone receptor HR+, HER2-low or -ultralow breast cancer.

Vimentin is a type III intermediate filament (IF) protein normally expressed in cells that develop into connective tissue, ...

Changes to the intermediate filament (IF) protein, vimentin, were found to promote tumor growth by increasing cancer stemness in an oestrogen independent manner.

Findings showed datopotamab deruxtecan reduced the risk of disease progression or death by 37% compared with chemotherapy.